Quest Diagnostics
DGX
227.93
+0.87
+0.38%
Quest Diagnostics
US · DGX
#767 by market cap
Listed 1996
227.93
+0.87
+0.38%
Live - 5344 symbols - heartbeat 457s ago
· 2026-10-08 09:59
Pre-market
228.13
+0.47%
After-hours
227.06
0.00%
- Market cap
- 25.16B
- P/E (TTM)i
- 24.20
- P/Bi
- 3.35
- EPSi
- 8.75
- Div yieldi
- 1.08%
- 52W posi
- 75%
Reader sentiment
Are you bullish or bearish on DGX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 11 analysts
Buy
Avg price target
255.00 +11.9%
Price target rangecurrent 227.93
Low245.00
Avg255.00
High265.00
Buy 64%
Hold 36%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-23 | Barclays | -- | BUY | 250.00 |
| 2026-09-22 | Truist Financial | -- | HOLD | 260.00 |
| 2026-09-21 | Truist Financial | -- | HOLD | 260.00 |
| 2026-09-08 | UBS | -- | HOLD | 245.00 |
| 2026-08-19 | Morgan Stanley | -- | BUY | 260.00 |
| 2026-07-28 | Argus Research | -- | BUY | 260.00 |
| 2026-07-28 | Mizuho Securities | -- | BUY | 260.00 |
| 2026-07-28 | Truist Financial | -- | HOLD | 250.00 |
| 2026-07-28 | J.P. Morgan | -- | HOLD | 250.00 |
| 2026-07-24 | UBS | -- | HOLD | 232.00 |
| 2026-07-24 | Mizuho Securities | -- | BUY | 260.00 |
| 2026-07-24 | BofA Securities | -- | BUY | 265.00 |
| 2026-07-24 | Truist Financial | -- | HOLD | 250.00 |
| 2026-07-24 | Baird | -- | HOLD | 255.00 |
| 2026-07-24 | Morgan Stanley | -- | BUY | 260.00 |
| 2026-07-24 | Barclays | -- | BUY | 250.00 |
| 2026-07-23 | William Blair | -- | BUY | -- |
| 2026-07-23 | Jefferies | -- | BUY | 245.00 |
| 2026-07-23 | Barclays | -- | BUY | 250.00 |
| 2026-07-15 | Barclays | -- | BUY | 230.00 |
| 2026-07-13 | BofA Securities | -- | BUY | 245.00 |
| 2026-07-13 | Baird | -- | HOLD | 236.00 |
| 2026-06-09 | Morgan Stanley | -- | BUY | 226.00 |
| 2026-05-06 | J.P. Morgan | -- | HOLD | 220.00 |
| 2026-04-22 | UBS | -- | HOLD | 220.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
C-
Momentum strategy signal
Buy
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Barclays moved from Hold to Buy on 2026-01-30.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-01-30 | Barclays | HOLD → BUY | 210.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-23 | -- | ±7.08% | +8.61% (beat) |
| 2026/Q1 | 2026-04-21 | -- | ±5.69% | +4.45% (in line) |
| 2025/Q4 | 2026-02-10 | -- | ±4.19% | +7.37% (beat) |
| 2025/Q3 | 2025-10-21 | -- | ±6.54% | -3.03% (in line) |
| 2025/Q2 | 2025-07-22 | -- | ±6.86% | +7.08% (beat) |
| 2025/Q1 | 2025-04-22 | -- | ±7.82% | +6.78% (in line) |
| 2024/Q4 | 2025-01-30 | -- | ±6.16% | +5.62% (in line) |
| 2024/Q3 | 2024-10-22 | -- | ±7.42% | +6.85% (in line) |
| 2024/Q2 | 2024-07-23 | -- | ±6.69% | -4.34% (in line) |
| 2024/Q1 | 2024-04-23 | -- | ±6.13% | +5.08% (in line) |
| 2023/Q4 | 2024-02-01 | -- | ±5.75% | -0.98% (in line) |
| 2023/Q3 | 2023-10-24 | -- | ±7.24% | +1.75% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 09:59:56 · For reference only, not investment advice and not tailored to your situation.